$WGBS Receives Notice of Patent Grant and Allowanc
Post# of 250671
Posted On: 10/28/2015 12:03:26 PM
$WGBS Receives Notice of Patent Grant and Allowance for Methods and Systems Utilizing Multi-Well Chips
WaferGen Bio-systems, Inc.
2 hours ago
GlobeNewswire
????
Related Quotes
WGBS
0.9501
-1.03%
WaferGen Bio-systems, Inc.? Watchlist
0.9501-0.0099(-1.03%)
NASDAQ10:17 AM EDT
8:02 am WaferGen Bio-Systems receives a notice of patent grant and allowance for methods and systems utilizing multi-well chips Briefing.com 2 hrs 16 mins ago
WAFERGEN BIO-SYSTEMS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan EDGAR Online 6 days ago
More
FREMONT, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- WaferGen Bio-systems, Inc. (WGBS) today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent 9,132,427 and has issued a Notice of Allowance for U.S. Patent Application 12/624,399 with both method and system claims utilizing multi-well chips, respectively. With the grant and allowance of these applications, WaferGen now owns five total issued patents, and one allowed application, that cover multiple salient attributes of the Company's SmartChip(TM) technology.
This family of patents provides greater strength for WaferGen's core SmartChip products and applications. These products include the recently launched ICELL8(TM) Single-Cell System, as well as the existing SmartChip Target Enrichment and Real-Time PCR systems. The ICELL8 System is a revolutionary single-cell system for processing thousands of single cells for downstream analysis, including Next Generation Sequencing (NGS). The system has the potential to accelerate the drug discovery and development process, and could uncover discoveries leading to clinical single-cell applications. The SmartChip Target Enrichment and Real-Time PCR systems are currently used in multiple clinical research applications, such as the identification of variants within the BRCA1 and BRCA2 genes via NGS.
"The granting and allowance of these applications complements our growing patent portfolio related to the SmartChip technology, and provides a solid foundation for our ICELL8 Single-Cell System, which employs the SmartChip technology," commented Rollie Carlson, President and CEO of WaferGen Bio-Systems. "Our additional filings of 17 U.S. and international patent applications related to single-cell analysis using the SmartChip technology, including single-cell capture, dispensing, counting, visualizing, and analysis, is expected to further strengthen WaferGen's position as the large-scale single cell analysis leader."
WaferGen Bio-systems, Inc.
2 hours ago
GlobeNewswire
????
Related Quotes
WGBS
0.9501
-1.03%
WaferGen Bio-systems, Inc.? Watchlist
0.9501-0.0099(-1.03%)
NASDAQ10:17 AM EDT
8:02 am WaferGen Bio-Systems receives a notice of patent grant and allowance for methods and systems utilizing multi-well chips Briefing.com 2 hrs 16 mins ago
WAFERGEN BIO-SYSTEMS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan EDGAR Online 6 days ago
More
FREMONT, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- WaferGen Bio-systems, Inc. (WGBS) today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent 9,132,427 and has issued a Notice of Allowance for U.S. Patent Application 12/624,399 with both method and system claims utilizing multi-well chips, respectively. With the grant and allowance of these applications, WaferGen now owns five total issued patents, and one allowed application, that cover multiple salient attributes of the Company's SmartChip(TM) technology.
This family of patents provides greater strength for WaferGen's core SmartChip products and applications. These products include the recently launched ICELL8(TM) Single-Cell System, as well as the existing SmartChip Target Enrichment and Real-Time PCR systems. The ICELL8 System is a revolutionary single-cell system for processing thousands of single cells for downstream analysis, including Next Generation Sequencing (NGS). The system has the potential to accelerate the drug discovery and development process, and could uncover discoveries leading to clinical single-cell applications. The SmartChip Target Enrichment and Real-Time PCR systems are currently used in multiple clinical research applications, such as the identification of variants within the BRCA1 and BRCA2 genes via NGS.
"The granting and allowance of these applications complements our growing patent portfolio related to the SmartChip technology, and provides a solid foundation for our ICELL8 Single-Cell System, which employs the SmartChip technology," commented Rollie Carlson, President and CEO of WaferGen Bio-Systems. "Our additional filings of 17 U.S. and international patent applications related to single-cell analysis using the SmartChip technology, including single-cell capture, dispensing, counting, visualizing, and analysis, is expected to further strengthen WaferGen's position as the large-scale single cell analysis leader."
(0)
(0)